CJC-1295/Ipamorelin Blend 5mg/5mg (No DAC) (10mg)

What is CJC-1295/Ipamorelin Blend?

CJC-1295/Ipamorelin Blend is a research-grade combination peptide containing 5 mg of CJC-1295 (no DAC), also known as Modified GRF(1-29), and 5 mg of Ipamorelin in a single lyophilized vial. This formulation brings together two of the most extensively studied growth hormone (GH) secretagogues, each operating through a distinct receptor pathway, to facilitate synergistic amplification of GH release in experimental models.

CJC-1295 no DAC is a 29-amino-acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH). Its molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂, with a molecular weight of approximately 3,367.9 Da. It features four key amino acid substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu) relative to native GRF(1-29), which confer enhanced resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and other proteases (Jetté et al., 2005).

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Its molecular formula is C₃₈H₄₉N₉O₅, with a molecular weight of approximately 711.85 Da. Designated NNC 26-0161 during development, ipamorelin was characterized as the first selective growth hormone secretagogue (GHS) — meaning it stimulates GH release without significantly affecting adrenocorticotropic hormone (ACTH), cortisol, or prolactin levels (Raun et al., 1998). The combined molecular weight of this blend is approximately 4,079.8 Da.

Mechanism of Action

The CJC-1295/Ipamorelin Blend derives its research value from the complementary dual-pathway activation of pituitary somatotroph cells. Each component engages a separate receptor system, and when administered together, the two peptides produce a synergistic GH response that exceeds the sum of their individual effects.

CJC-1295 (Modified GRF 1-29): GHRH Receptor Pathway

CJC-1295 no DAC binds to the growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor (GPCR) expressed on anterior pituitary somatotrophs. Upon receptor engagement, CJC-1295 activates adenylyl cyclase via the Gα_s subunit, increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. This cAMP elevation activates protein kinase A (PKA), which phosphorylates downstream targets including the transcription factor CREB (cAMP response element-binding protein). The net effect is both an acute release of stored GH granules and longer-term upregulation of GH gene transcription (Teichman et al., 2006). Research in GHRH knockout (GHRHKO) mice demonstrated that daily CJC-1295 administration restored normal growth parameters and body composition, confirming its action through the GHRH-R pathway (Alba et al., 2006).

Ipamorelin: GHS Receptor (Ghrelin Receptor) Pathway

Ipamorelin binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Activation of GHS-R1a triggers the phospholipase C (PLC)/inositol trisphosphate (IP₃) signaling cascade, leading to the release of calcium from intracellular stores and a subsequent influx of extracellular calcium. This calcium surge induces rapid exocytosis of GH vesicles. Importantly, Raun et al. (1998) demonstrated that ipamorelin displays a selectivity profile for GH release comparable to that of GHRH itself — it does not significantly elevate ACTH, cortisol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), or thyroid-stimulating hormone (TSH), even at doses more than 200-fold above the ED₅₀ for GH release (Raun et al., 1998).

Synergistic Amplification

The simultaneous engagement of both the GHRH-R (via CJC-1295) and GHS-R1a (via Ipamorelin) produces a well-documented synergistic GH release. Bowers et al. (1991) were among the first to describe this phenomenon, demonstrating that combined GHRH and GHRP administration resulted in dramatically amplified GH secretion that could not be explained by simple addition of the two pathways (Bowers et al., 1991). Hanew et al. (1994) confirmed in clinical subjects that GHRP administered with GHRH produced synergistically enhanced plasma GH responses (Hanew et al., 1994). This synergy arises because GHRH provides the sustained cAMP-dependent “priming” signal while the GHRP pathway delivers the acute calcium-dependent “trigger” for GH exocytosis. Together, they maximize both the amplitude and duration of GH pulsatility.

Research Applications

The CJC-1295/Ipamorelin Blend has attracted substantial research interest across multiple domains due to its potent and selective amplification of the GH/IGF-1 axis. Below are the primary areas of investigation.

Growth Hormone Optimization and GH/IGF-1 Axis Research

The primary application of this blend in research settings is the study of growth hormone releasing peptides and their capacity to elevate endogenous GH and insulin-like growth factor 1 (IGF-1). Teichman et al. (2006) demonstrated that CJC-1295 alone produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold and IGF-1 concentrations by 1.5- to 3-fold in healthy subjects (Teichman et al., 2006). When combined with a GHS-R1a agonist such as Ipamorelin, research protocols can investigate whether the synergistic GH response translates into proportionally greater IGF-1 elevations and downstream anabolic signaling. Sackmann-Sala et al. (2009) further showed that CJC-1295-mediated GH/IGF-1 axis activation produced measurable changes in serum protein profiles, suggesting broad metabolic effects beyond simple GH elevation (Sackmann-Sala et al., 2009).

Body Composition and Metabolic Research

The GH/IGF-1 axis plays a central role in the regulation of lean body mass and adipose tissue metabolism. Studies on GH secretagogues indicate their potential to influence body composition parameters in experimental models. Alba et al. (2006) showed that CJC-1295 treatment maintained normal body composition in GHRH-deficient mice, including the preservation of lean mass and limitation of fat accumulation (Alba et al., 2006). The combination of a GHRH analog with a GHRP in peptide stack protocols allows researchers to evaluate whether synergistic GH output offers advantages in body composition endpoints compared to single-agent approaches. Investigations exploring peptides for weight loss research frequently incorporate this blend due to its dual-mechanism GH amplification.

Bone and Skeletal Tissue Research

Ipamorelin has been independently studied for its effects on skeletal tissue. Johansen et al. (1999) demonstrated that ipamorelin dose-dependently increased longitudinal bone growth rate in adult female rats, from 42 μm/day in vehicle controls to 52 μm/day at the highest dose (Johansen et al., 1999). Svensson et al. (2000) showed that 12 weeks of continuous ipamorelin administration increased total tibial and vertebral bone mineral content (BMC) in adult female rats as measured by dual-energy X-ray absorptiometry (DXA) (Svensson et al., 2000). Additionally, Andersen et al. (2001) found that ipamorelin counteracted glucocorticoid-induced decreases in bone formation markers in adult rats (Andersen et al., 2001). These findings make the blend valuable for research investigating peptides for joint and bone support.

Anti-Aging and Age-Related GH Decline Research

Endogenous GH secretion declines progressively with age, a phenomenon known as somatopause. Researchers studying peptides for anti-aging research use the CJC-1295/Ipamorelin Blend to investigate whether restoring pulsatile GH secretion through dual-pathway stimulation can counteract age-associated physiological changes. Because both peptides work through endogenous feedback mechanisms rather than introducing exogenous GH, research protocols can examine whether this approach maintains more physiological GH pulsatility patterns compared to direct GH administration.

Gastrointestinal Motility Research

Ipamorelin’s activity at the GHS-R1a receptor, which is widely distributed in the gastrointestinal (GI) tract, has led to investigations of its prokinetic effects. Venkova et al. (2016) demonstrated that ipamorelin accelerated gastric emptying in a rodent model of postoperative ileus, highlighting its potential as a GI motility agent acting through ghrelin receptor pathways (Venkova et al., 2016). This application is distinct from the GH-releasing properties and expands the research utility of the blend.

Published Research Studies

The following peer-reviewed studies form the core evidence base supporting research with the CJC-1295/Ipamorelin Blend and its individual components.

Teichman et al. (2006) – CJC-1295 in Healthy Adults

In a pair of randomized, placebo-controlled, double-blind ascending dose trials, Teichman et al. (2006) evaluated CJC-1295 in healthy subjects aged 21–61 years. Subcutaneous CJC-1295 produced dose-dependent GH increases of 2- to 10-fold sustained for 6 or more days, and IGF-1 increases of 1.5- to 3-fold lasting 9–11 days after a single injection. Multiple doses demonstrated a cumulative effect with IGF-1 remaining elevated above baseline for up to 28 days. Published in the Journal of Clinical Endocrinology & Metabolism.

Raun et al. (1998) – Ipamorelin Selectivity Profile

Raun et al. (1998) characterized ipamorelin as the first selective GH secretagogue. In both rat pituitary cell cultures and conscious swine, ipamorelin released GH with potency and efficacy comparable to GHRP-6 (ED₅₀ = 2.3 nmol/kg in swine). Crucially, ipamorelin did not affect ACTH or cortisol levels even at doses exceeding the GH ED₅₀ by more than 200-fold, establishing its unique selectivity. Published in the European Journal of Endocrinology.

Bowers et al. (1991) – GHRH/GHRP Synergy

Bowers et al. (1991) provided foundational evidence for the synergistic interaction between GHRH and growth hormone-releasing peptides. The study demonstrated that the combined GH release from GHRP plus GHRH exceeded what could be explained by additive effects, somatostatin inhibition, or GHRH stimulation alone, establishing the principle of complementary dual-pathway activation. Published in Endocrinology.

Svensson et al. (2000) – Ipamorelin and Bone Mineral Content

Svensson et al. (2000) administered ipamorelin (0.5 mg/kg/day) via subcutaneous osmotic minipumps for 12 weeks in adult female rats. DXA measurements revealed significant increases in total tibial and vertebral BMC. In vitro pQCT analysis showed that the cortical BMC increase was attributable to increased cross-sectional bone area rather than volumetric density changes. Published in the Journal of Endocrinology.

Alba et al. (2006) – CJC-1295 in GHRH Knockout Mice

Alba et al. (2006) demonstrated that once-daily administration of CJC-1295 normalized growth and body composition in GHRH knockout mice. The study confirmed that CJC-1295 acts specifically through the GHRH receptor pathway and that sustained receptor activation can restore normal physiological parameters. Published in the American Journal of Physiology – Endocrinology and Metabolism.

Dosage Protocols in Research

Note: The following information reflects dosages reported in published preclinical and clinical research studies. All data is presented for research purposes only.

CJC-1295 (no DAC) Dosing in Published Studies

In the clinical trial by Teichman et al. (2006), CJC-1295 was administered subcutaneously at doses ranging from 30 to 60 μg/kg in single and multiple dose protocols (Teichman et al., 2006). The 30 and 60 μg/kg doses were noted as being well tolerated with sustained GH/IGF-1 elevation. In the GHRHKO mouse model, Alba et al. (2006) used daily subcutaneous injections to normalize growth parameters (Alba et al., 2006).

Ipamorelin Dosing in Published Studies

Johansen et al. (1999) administered ipamorelin at 18, 90, and 450 μg/day (divided into three daily subcutaneous injections) over 15 days in female rats, with dose-dependent increases in longitudinal bone growth rate (Johansen et al., 1999). Svensson et al. (2000) used continuous infusion at 0.5 mg/kg/day via osmotic minipumps over 12 weeks (Svensson et al., 2000). In the selectivity study by Raun et al. (1998), the ED₅₀ for GH release was 80 nmol/kg in anaesthetized rats and 2.3 nmol/kg in conscious swine.

Reconstitution Guidelines for Research

This blend is supplied as a lyophilized powder containing 5 mg CJC-1295 (no DAC) and 5 mg Ipamorelin. For reconstitution, add bacteriostatic water (0.9% benzyl alcohol) slowly along the inside wall of the vial. A common research reconstitution volume is 2 mL of bacteriostatic water, yielding a concentration of 2.5 mg/mL for each peptide component. Allow the powder to dissolve completely without shaking — gentle swirling is acceptable. For detailed reconstitution instructions, refer to our guide on how to reconstitute peptides.

Storage and Handling

Proper storage is essential to maintain the integrity and biological activity of the CJC-1295/Ipamorelin Blend. As a lyophilized peptide product, it should be stored according to the following guidelines to ensure consistency across research protocols.

Before reconstitution: Store the sealed vial at -20°C for long-term storage (up to 24 months) or at 2–8°C (standard refrigeration) for short-term storage of up to 3 months. Keep the vial in its original packaging, protected from light and moisture. Do not expose to repeated freeze-thaw cycles.

After reconstitution: Store the reconstituted solution at 2–8°C (refrigerated). Use reconstituted peptide within 4–6 weeks for optimal potency. Do not freeze reconstituted solutions, as this may cause degradation or aggregation of the peptide chains. Use sterile technique for all handling to prevent microbial contamination.

General handling: Avoid vigorous shaking, which can cause peptide denaturation and foaming. Protect from direct sunlight and UV exposure at all times. Use insulin-grade syringes to minimize dead volume loss during aspiration. For comprehensive storage advice, visit our guide on how to store research peptides.

Safety Profile in Research

The safety data for the CJC-1295/Ipamorelin Blend draws primarily from published studies on each individual component, as both have been extensively investigated in animal and limited clinical research models.

Ipamorelin Safety Data

The defining safety advantage of ipamorelin is its selectivity. Raun et al. (1998) demonstrated that ipamorelin did not significantly elevate ACTH, cortisol, FSH, LH, PRL, or TSH plasma levels in swine, even at doses exceeding the GH-releasing ED₅₀ by more than 200-fold (Raun et al., 1998). This stands in contrast to other growth hormone secretagogues such as GHRP-6 and GHRP-2, which have been shown to increase ACTH and cortisol levels. In long-term dosing studies, Johansen et al. (1999) reported no significant adverse effects during 15 days of subcutaneous ipamorelin administration in rats (Johansen et al., 1999).

CJC-1295 Safety Data

Teichman et al. (2006) reported that subcutaneous CJC-1295 was safe and relatively well tolerated in healthy adults. The most commonly reported effects were injection-site reactions, transient flushing, and headache. No serious adverse reactions were noted across both single-dose and multiple-dose protocols at doses up to 60 μg/kg (Teichman et al., 2006).

Combination Considerations

Because the two peptides act on distinct receptors, the combination is not expected to produce novel off-target effects beyond those documented for each individual component. However, the amplified GH response from synergistic activation may increase the incidence of GH-related effects such as transient water retention, joint stiffness, or numbness/tingling in research subjects. Researchers should refer to the research peptide safety guide for comprehensive precautions when working with GH secretagogues.

Related Peptides

The CJC-1295/Ipamorelin Blend belongs to the broader category of growth hormone secretagogues. Researchers studying this combination may also be interested in the individual components and related compounds:

• CJC-1295 No DAC 10mg – The standalone GHRH analog (Modified GRF 1-29), useful for protocols where independent dosing control of the GHRH component is required.
• Ipamorelin 10mg – The standalone selective GHS, ideal for studies requiring independent titration of the ghrelin-receptor agonist component.
• CJC-1295 with DAC 5mg – The Drug Affinity Complex version that covalently binds albumin for extended half-life. Learn more in our CJC-1295 DAC vs. No DAC comparison.
• Sermorelin 10mg – The unmodified GRF(1-29) GHRH analog, compared in detail in our Sermorelin vs. Ipamorelin comparison.
• MK-677 (Ibutamoren) – An oral, non-peptide GHS-R1a agonist used in research as a long-acting alternative to injectable GH secretagogues.
• Tesamorelin 10mg – Another GHRH analog studied primarily in the context of visceral adiposity and metabolic research.

Frequently Asked Questions

What is CJC-1295/Ipamorelin Blend used for in research?

The CJC-1295/Ipamorelin Blend is used in research to investigate the synergistic amplification of growth hormone release through simultaneous activation of the GHRH receptor (via CJC-1295) and the ghrelin/GHS-R1a receptor (via Ipamorelin). Research applications include GH/IGF-1 axis optimization, body composition studies, skeletal tissue research, anti-aging investigation, and gastrointestinal motility studies. It is sold strictly for research purposes only and is not intended for human consumption.

How does the CJC-1295/Ipamorelin Blend produce synergistic effects?

The synergy arises from the complementary activation of two distinct intracellular signaling cascades within pituitary somatotroph cells. CJC-1295 activates the cAMP/PKA pathway through GHRH receptors, while Ipamorelin triggers the PLC/IP₃/calcium pathway through GHS-R1a receptors. The combined stimulation produces GH release that is significantly greater than the sum of each peptide administered alone, as demonstrated by Bowers et al. (1991) and Hanew et al. (1994).

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC (Drug Affinity Complex) contains a maleimido group that covalently binds to serum albumin after injection, extending the half-life to 5–8 days and producing continuous GH elevation. CJC-1295 without DAC (Modified GRF 1-29), used in this blend, has a shorter half-life of approximately 30 minutes, producing pulsatile GH release that more closely mimics natural physiology. The no-DAC version is generally preferred for combination protocols. For a complete comparison, see our CJC-1295 DAC vs. No DAC guide.

Why is Ipamorelin preferred over other GHRPs like GHRP-6 or GHRP-2?

Ipamorelin is the first and only growth hormone secretagogue demonstrated to have GH selectivity comparable to GHRH itself. Unlike GHRP-6 and GHRP-2, which significantly elevate ACTH, cortisol, and in some cases prolactin, ipamorelin does not meaningfully affect these hormones even at very high doses (Raun et al., 1998). This selectivity reduces confounding variables in research protocols and provides a cleaner GH-specific signal for experimental studies. Learn more in our Ipamorelin research guide.

What are the advantages of a pre-blended vial vs. separate vials?

A pre-blended vial offers several practical advantages for research. It eliminates the need for two separate reconstitutions and two separate injections per time point, reducing preparation time and potential for dosing errors. The fixed 1:1 ratio (5 mg to 5 mg) simplifies protocol design for studies investigating the standard combination. For research requiring independent dose titration of each component, the standalone CJC-1295 No DAC and Ipamorelin products are recommended.

How should this blend be reconstituted and stored?

Add 2 mL of bacteriostatic water slowly along the vial wall. Allow the lyophilized powder to dissolve completely without shaking. This yields a concentration of 2.5 mg/mL for each peptide. Store reconstituted solution at 2–8°C and use within 4–6 weeks. Unreconstituted vials should be stored at -20°C for long-term or 2–8°C for short-term storage. See our reconstitution guide for step-by-step instructions.

Can CJC-1295/Ipamorelin Blend be used with other peptides in research?

Yes, this blend is frequently incorporated into multi-peptide research protocols. Common research combinations explored in the literature include GH secretagogues paired with tissue-repair peptides such as BPC-157 or TB-500. For guidance on combining research peptides, see our best peptide stack combinations guide.

Why Buy CJC-1295/Ipamorelin Blend from Iron Peak Peptides?

Iron Peak Peptides is committed to providing the highest quality research peptides backed by rigorous quality assurance at every stage of production.

Third-Party Testing: Every batch of our CJC-1295/Ipamorelin Blend undergoes independent third-party testing via high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to verify identity, purity, and the accurate 5 mg/5 mg ratio of both peptide components.

Purity Guarantee: We guarantee a minimum purity of ≥99% for each peptide in the blend, ensuring reliable and reproducible results across your research protocols.

quality assurance documentation: A detailed quality assurance documentation (CoA) is available for every batch, documenting HPLC purity data, MS confirmation of molecular weight, endotoxin testing results, and sterility verification.

Proper Handling: All peptides are manufactured under strict quality controls, lyophilized under optimal conditions, and shipped with appropriate cold-chain packaging to preserve stability during transit.

Research Support: Our team provides technical guidance on reconstitution, storage, and general peptide handling to support your research objectives. When you choose Iron Peak Peptides, you are choosing a partner dedicated to advancing peptide science with integrity and precision.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhargava AK. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
3. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128(4):2027-2035. PubMed
4. Hanew K, Utsumi A, Sugawara A, Shimizu Y, Abe K. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly. J Clin Endocrinol Metab. 1994;78(3):509-512. PubMed
5. Alba M, Fintini D, Bowers CY, Parlow AF, Bhargava AK. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PubMed
6. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PubMed
7. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PubMed
8. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PubMed
9. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PubMed
10. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-272. PubMed
11. Venkova K, Fraser G, Hoveyda HR, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. PubMed
12. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing factor analogue, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. PubMed

Further Research

Preclinical investigations confirm that combined GHRH analog and GHSR-1a agonist administration produces synergistic GH release that consistently exceeds monotherapy levels across multiple model systems — a principle extensively documented by Bowers et al. (PMID: 7616863). Ipamorelin’s selective GH stimulation without concurrent ACTH or cortisol elevation (Raun et al., 1998; PMID: 9849822) makes this blend a high-specificity dual-pathway GH secretagogue combination for experimental research designs requiring clean hormonal background.

For a comprehensive mechanistic overview, comparative analysis of CJC No DAC vs. CJC with DAC vs. Sermorelin and Tesamorelin, and detailed sourcing criteria, see IronPeak’s dedicated resource: CJC-1295 / Ipamorelin Blend (No DAC): Complete Research Guide & Where to Source (2026).